TP与EP方案治疗晚期非小细胞肺癌的临床对比观察

目的评价紫杉醇联合顺铂方案(TP)与足叶乙甙联合顺铂方案(EP)治疗晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。方法56例晚期非小细胞肺癌随机分成两组:TP组28例,紫杉醇60mg/m2,静脉滴注,第1、8、15天;顺铂30mg/m2,静脉滴注第2-4天。EP组28例,足叶乙甙100mg,静脉滴注,第1-5天;顺铂用法同TP组。4周为一周期。结果近期有效率TP组与EP组分别为57.1%与32.1%,两组统计学有差异(P<0.05);中位疾病进展时间TP组与EP组分别为5.4个月与3.5个月,两组统计学有差异(P<0.05);中位生存时间TP组与EP组分别为10.5个月与7.6个月,两组统计学无差异(P>0.05);一年生存率TP组与EP组分别为42.9%与28.6%,两组统计学有差异(P<0.05)。两组毒副反应相似。结论TP组在近期有效率、中位疾病进展时间及一年生存率较EP组占优势,而中位生存时间两组相近。

Clinic comparative study of TP and EP chemotherapy for advanced NSCLC cancer

Objective To evaluate the effect and toxicity of Paclitaxil plas Cisplatin vs Etoposide plas Cisplatin for advanced NSCLC cancer. Methods Fifty-six patients with advanced NSCLC cancer were divided into two groups.TP group(28 cases) received Paclitaxil 60mg/m2 infusion on D1,D8,D15; Cisplatin 30mg/m~2 infusion on D2 to D4.EP group(28 cases) received Etoposide 100mg infusion on D1-D5,Cisplatin were carried out in the same methods as TP groups. Each course was repeated every 4 weeks. Results the effective rate for TP groups and EPgroups were 57.1%, 32.1%, respectively, and showed a statistically difference (P<0.05) ,median time to progression(mTTP)for TP groups and EP groups were 5.4months,3.5 months, respectively, and showed a statistically significant difference (P<0.05) .median survival time for TP groups and EPgroups were 10.5months,7.6 months, respectively, and no significant difference (P>0.05).one-year survival rate for TP groups and EPgroups were 42.9%, 28.6%, respectively, and showed a statistically significant difference (P<0.05) .the toxiticy in two groups were similar. Conclusion the effective rate ,median time to progression, one-year survival rate of TP groups were better than those of EP groups ,and median survival time in two groups was similar .